A Sequential Benznidazole–Vaccine–Benznidazole Regimen Enhances Therapeutic Efficacy Against Chronic Trypanosoma cruzi Infection in Mice

Background/Objectives: Chronic Chagas cardiomyopathy (CCC), caused by Trypanosoma cruzi (T. cruzi), remains a major public health challenge and a leading cause of heart failure, with this chronic stage representing the period when most patients are diagnosed and require clinical intervention. However, the efficacy of the available parasiticidal drugs, benznidazole (BZL) and nifurtimox during chronic infection is limited and new therapeutic approaches are needed. In this study, we evaluated a novel sequential chemo-immunotherapeutic strategy (BZL → Vac → BZL) designed to shorten benznidazole treatment duration to minimize drug-related adverse effects by leveraging the synergistic potential of both treatments. Methods: BALB/c mice chronically infected with T. cruzi were used as model. A long-term sequential regimen was evaluated and compared 190 days post-infection with uninfected, untreated infected (Tc), monotherapy (BZL or TSNt-ISPA vaccine), and combined (Vac → BZL) controls. The sequential treatment consisted of an initial short cycle of oral BZL, three subcutaneous immunizations with the TSNt-ISPA vaccine, and a final BZL booster. Cardiac parasite load and cytokine expression (qPCR), inflammation and fibrosis (histopathology), electrocardiograms (ECG), specific antibodies (ELISA), and splenic cellular response (flow cytometry) were analyzed. Results: The BZL-Vac → BZL scheme significantly reduced cardiac parasite load, achieving undetectability in some animals. Combined therapies (Vac → BZL and BZL → Vac → BZL) significantly attenuated myocardial inflammation and fibrosis, improving P-wave duration and the QTc interval. The sequential treatment induced a robust Th1-associated humoral response (IgG2a) and a balanced cellular profile, uniquely increasing splenic IL-10-producing CD4+ T cells, TNF-α-producing CD8+ T cells, and cardiac IL-10 and Foxp3 expression. Conclusions: The temporal integration of fractionated benznidazole and TSNt-ISPA immunotherapy protects myocardial integrity and function through an effector immune response under strict regulatory control.

Authors

Institutions

Publication Details

Journal
Vaccines
Published
2026-11-17
DOI
https://doi.org/10.3390/vaccines14110993
Primary Topic
Trypanosoma species research and implications
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Sequential Benznidazole–Vaccine–Benznidazole Regimen Enhances Therapeutic Efficacy Against Chronic Trypanosoma cruzi Infection in Mice

Cecilia Farré, Camila Bulfoni Balbi, Ivan Sergio Marcipar, Brenda Dinatale et al.
Vaccines
Trypanosoma species research and implications
article

A Sequential Benznidazole–Vaccine–Benznidazole Regimen Enhances Therapeutic Efficacy Against Chronic Trypanosoma cruzi Infection in Mice

Cecilia Farré, Camila Bulfoni Balbi, Ivan Sergio Marcipar, Brenda Dinatale, Ana Rosa Pérez, Estefanía Prochetto, Florencia Belén González, María Florencia Pacini, Paula Cacik, Genaro Francisco Díaz, Ulises Cha
article en

Abstract

Background/Objectives: Chronic Chagas cardiomyopathy (CCC), caused by Trypanosoma cruzi (T. cruzi), remains a major public health challenge and a leading cause of heart failure, with this chronic stage representing the period when most patients are diagnosed and require clinical intervention. However, the efficacy of the available parasiticidal drugs, benznidazole (BZL) and nifurtimox during chronic infection is limited and new therapeutic approaches are needed. In this study, we evaluated a novel sequential chemo-immunotherapeutic strategy (BZL → Vac → BZL) designed to shorten benznidazole treatment duration to minimize drug-related adverse effects by leveraging the synergistic potential of both treatments. Methods: BALB/c mice chronically infected with T. cruzi were used as model. A long-term sequential regimen was evaluated and compared 190 days post-infection with uninfected, untreated infected (Tc), monotherapy (BZL or TSNt-ISPA vaccine), and combined (Vac → BZL) controls. The sequential treatment consisted of an initial short cycle of oral BZL, three subcutaneous immunizations with the TSNt-ISPA vaccine, and a final BZL booster. Cardiac parasite load and cytokine expression (qPCR), inflammation and fibrosis (histopathology), electrocardiograms (ECG), specific antibodies (ELISA), and splenic cellular response (flow cytometry) were analyzed. Results: The BZL-Vac → BZL scheme significantly reduced cardiac parasite load, achieving undetectability in some animals. Combined therapies (Vac → BZL and BZL → Vac → BZL) significantly attenuated myocardial inflammation and fibrosis, improving P-wave duration and the QTc interval. The sequential treatment induced a robust Th1-associated humoral response (IgG2a) and a balanced cellular profile, uniquely increasing splenic IL-10-producing CD4+ T cells, TNF-α-producing CD8+ T cells, and cardiac IL-10 and Foxp3 expression. Conclusions: The temporal integration of fractionated benznidazole and TSNt-ISPA immunotherapy protects myocardial integrity and function through an effector immune response under strict regulatory control.

VaccinesVol. 14(11)
Consejo Nacional de Investigaciones Científicas y Técnicas (AR), Universidad Nacional del Litoral (AR), National University of Rosario (AR)
Trypanosoma species research and implications
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon